Navidea Biopharmaceuticals to Present at the Cowen & Company 33rd Annual
Health Care Conference
Chief Business Officer to Provide Business and Development Program Updates
Cowen Group Healthcare Conference 2013
DUBLIN, Ohio -- February 28, 2013
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that Dr.
Thomas Tulip, Executive Vice President and Chief Business Officer, will
participate at the Cowen & Company 33^rd Annual Health Care Conference on
March 4 - 6, 2013 at the Boston Marriott Copley Place, Boston, Massachusetts.
Dr. Tulip will provide an update of the Company and its development programs
on Tuesday, March 5, 2013 at 9:20 AM EST.
Investors and the public are invited to listen to a live webcast of Dr.
Tulip’s presentation at http://wsw.com/webcast/cowen10/navb/. Following the
conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
Brent Larson, 614-822-2330
Sr. VP & CFO
Press spacebar to pause and continue. Press esc to stop.